Drugs / Recombinant Interferon Alfa 2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02829775 | Jan 2004 → Jan 2008 | chronic myeloid leukemia, melanoma, renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Interferon Alfa 2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02829775 ↗ |
| Route | Subcutaneous | “recombinant interferon alfa 2A will be administered subcutaneously once daily” NCT02829775 ↗ |